Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington's disease

Parkinsonism and Related Disorders

Volumn 15, Issue 3, 2009, Pages 245-248

  Constantinescu, Radu ^a   Romer, Megan ^b   Oakes, David ^c   Rosengren, Lars ^a   Kieburtz, Karl ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Cerebrospinal fluid; Huntington's disease; Neurofilament

Indexed keywords

NEUROFILAMENT PROTEIN; PLACEBO;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RATING SCALE;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; NEUROFILAMENT PROTEINS; NEUROPSYCHOLOGICAL TESTS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 60549106196     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2008.05.012     Document Type: Article

References (17)

1. Hoffman P.N., Cleveland D.W., Griffin J.W., Landes P.W., Cowan N.J., and Price D.L. Neurofilament gene expression: a major determinant of axonal caliber. Proc Natl Acad Sci U S A 84 (1987) 3472-3476
2. Norgren N., Rosengren L., and Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res 987 (2003) 25-31
3. DiProspero N.A., Chen E.Y., Charles V., Plomann M., Kordower J.H., and Tagle D.A. Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements. J Neurocytol 33 (2004) 517-533
4. The Huntington Study Group. Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease. Neurology 50 (1998) 1366-1373
5. Shoulson I., Kurlan R., and Rubin A. Assessment of functional capacity in neurodegenerative movement disorders: Huntington's disease as a prototype. In: Munsat T. (Ed). Quantification of neurologic deficit (1989), Butterworths, Stoneham, MA 271-283
6. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 11 (1996) 136-142
7. Rosengren L.E., Karlsson J.E., Karlsson J.O., Persson L.I., and Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 67 (1996) 2013-2018
8. Holmberg B., Rosengren L., Karlsson J.E., and Johnels B. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease. Mov Disord 13 (1998) 70-77
9. Rosengren L.E., Karlsson J.E., Sjogren M., Blennow K., and Wallin A. Neurofilament protein levels in CSF are increased in dementia. Neurology 52 (1999) 1090-1093
10. Lycke J.N., Karlsson J.E., Andersen O., and Rosengren L.E. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 64 (1998) 402-404
11. Gisslen M., Hagberg L., Brew B.J., Cinque P., Price R.W., and Rosengren L. Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. J Infect Dis 195 (2007) 1774-1778
12. Andersson L.M., Hagberg L., Rosengren L., Fuchs D., Blennow K., and Gisslen M. Normalisation of cerebrospinal fluid biomarkers parallels improvement of neurological symptoms following HAART in HIV dementia - case report. BMC Infect Dis 6 (2006) 141
13. Rosas H.D., Koroshetz W.J., Chen Y.I., Skeuse C., Vangel M., Cudkowicz M.E., et al. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 60 10 (2003 May 27) 1615-1620
14. Albin R.L., Young A.B., Penney J.B., Handelin B., Balfour R., Anderson K.D., et al. Abnormalities of striatal projection neurons and N-methyl-d-aspartate receptors in presymptomatic Huntington's disease. N Engl J Med 322 (1990) 1293-1298
15. Rosas H.D., Tuch D.S., Hevelone N.D., Zaleta A.K., Vangel M., Hersch S.M., et al. Diffusion tensor imaging in presymptomatic and early Huntington's disease: selective white matter pathology and its relationship to clinical measures. Mov Disord 21 (2006) 1317-1325
16. Wild E.J., Petzold A., Keir G., and Tabrizi S.J. Plasma neurofilament heavy chain levels in Huntington's disease. Neurosci Lett 417 (2007) 231-233
17. Rosen H., Karlsson J.E., and Rosengren L. CSF levels of neurofilament is a valuable predictor of long-term outcome after cardiac arrest. J Neurol Sci 221 (2004) 19-24